Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ pharmacology
Antioxidants
/ pharmacology
Antiparkinson Agents
/ pharmacology
Astrocytes
/ drug effects
Corpus Striatum
/ drug effects
Drug Therapy, Combination
Gliosis
/ drug therapy
Male
Microglia
/ drug effects
Motor Activity
/ drug effects
Oxidative Stress
/ drug effects
Oxidopamine
Parkinsonian Disorders
/ drug therapy
Peptide Fragments
/ pharmacology
Pramipexole
/ pharmacology
Random Allocation
Rats, Wistar
Tetanus Toxin
/ pharmacology
Time Factors
6-Hydroxydopamine
Astrogliosis
Microgliosis
Oxidative stress
Parkinson’s disease
Superoxide dismutase
Tetanus toxin
Journal
Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
03
06
2018
accepted:
11
12
2018
revised:
05
12
2018
pubmed:
5
1
2019
medline:
16
5
2019
entrez:
5
1
2019
Statut:
ppublish
Résumé
Reports indicate that striatal dopaminergic damage induced by 6-hydoxydopamine (6-OHDA) can be blocked by C-terminal domain of tetanus toxin (Hc-TeTx), suggesting possible therapeutic potential of Hc-TeTx in Parkinson's disease (PD). Pramipexole (PPX), a D2/D3 dopaminergic agonist, is currently used in PD treatment. The purpose of this study was to gain some understanding of the actions of each drug, including potential antioxidant and anti-inflammatory effects and importantly, to determine whether the combination of the two drugs would be superior to each alone. Adult male Wistar rats were administered 6-OHDA into the dorso-lateral striatum, and the effects of Hc-TeTx fragment (20 μg/kg i.m. every 24 h) for 3 days; PPX (1 mg/kg p.o., every 12 h) for 30 days and their combination on various motor and neurochemical parameters were evaluated. Behavioral tests were carried out at 15 and 30 days post-treatments. At day 31, the animals were sacrificed and the levels of tyrosine hydroxylase (TH), reflecting dopaminergic activity in both striatum and substantia nigra, were evaluated. In addition, indices of astrogliosis, microgliosis, as well as oxidative stress in the striatum were determined. Both Hc-TeTx and PPX ameliorated the motor and neurochemical deficits induced by 6-OHDA lesion; however, the combination of the two drugs was not superior to each alone. Hence, at concentrations used in this study, no significant advantage in combining Hc-TeTx with PPX was noted. Although the results suggest similar neurochemical effects of the two compounds, further evaluation of different concentrations of Hc-TeTx and PPX as potential intervention in PD is warranted.
Identifiants
pubmed: 30607904
doi: 10.1007/s12640-018-9990-3
pii: 10.1007/s12640-018-9990-3
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antioxidants
0
Antiparkinson Agents
0
Peptide Fragments
0
Tetanus Toxin
0
tetanus toxin fragment C
0
Pramipexole
83619PEU5T
Oxidopamine
8HW4YBZ748
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-710Subventions
Organisme : PRODEP-SEP
ID : NPTC-472
Organisme : VIEP-BUAP
ID : 2017-2018
Organisme : FELLOWSHIP CONACYT-MEXICO
ID : 581481
Références
Neuropharmacology. 2000 Mar 3;39(5):777-87
pubmed: 10699444
Neurosci Lett. 2000 Mar 10;281(2-3):167-70
pubmed: 10704769
Biochem J. 2000 Apr 1;347 Pt 1:199-204
pubmed: 10727419
Physiol Rev. 2000 Apr;80(2):717-66
pubmed: 10747206
Annu Rev Neurosci. 2000;23:39-71
pubmed: 10845058
Mol Microbiol. 2000 Sep;37(5):1041-51
pubmed: 10972823
Neurochem Res. 2000 Oct;25(9-10):1439-51
pubmed: 11059815
J Neural Transm (Vienna). 2000;107(10):1165-73
pubmed: 11129106
Brain Res. 2001 Jun 29;905(1-2):44-53
pubmed: 11423078
Free Radic Biol Med. 2002 Aug 1;33(3):337-49
pubmed: 12126755
Mol Cell Neurosci. 2002 Aug;20(4):627-37
pubmed: 12213444
Biochem J. 2003 Jul 15;373(Pt 2):613-20
pubmed: 12710887
Trends Microbiol. 2003 Sep;11(9):431-7
pubmed: 13678859
Acta Neurobiol Exp (Wars). 2003;63(3):211-8
pubmed: 14518512
Brain Res. 2004 Jan 2;995(1):84-96
pubmed: 14644474
J Neurobiol. 2004 Feb 5;58(2):295-314
pubmed: 14704960
Brain Res. 2004 Jun 11;1011(1):7-13
pubmed: 15140640
J Neurochem. 2004 Sep;90(5):1227-36
pubmed: 15312177
BMC Biol. 2004 Oct 11;2:22
pubmed: 15473914
Mol Cell Neurosci. 2005 Dec;30(4):572-82
pubmed: 16456925
Pharmacology. 2006;77(1):38-45
pubmed: 16569938
Neuroscience. 2006 Aug 25;141(2):803-16
pubmed: 16713105
Annu Rev Genomics Hum Genet. 2006;7:103-24
pubmed: 16722804
J Cell Biol. 2006 Jul 31;174(3):459-71
pubmed: 16880274
Neurodegener Dis. 2004;1(2-3):101-8
pubmed: 16908981
J Neurosci Methods. 2007 Jan 30;159(2):195-202
pubmed: 16942799
Brain Res. 2006 Nov 20;1120(1):1-12
pubmed: 17020749
Neurotox Res. 2007 Apr;11(3-4):151-67
pubmed: 17449457
Exp Neurol. 2007 Nov;208(1):1-25
pubmed: 17720159
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76
pubmed: 18344392
Parkinsonism Relat Disord. 2008;14 Suppl 2:S124-9
pubmed: 18595767
Restor Neurol Neurosci. 2008;26(6):459-65
pubmed: 19096133
Toxicon. 2009 Oct;54(5):593-9
pubmed: 19264088
Mol Cell Neurosci. 2009 Jul;41(3):297-303
pubmed: 19344769
Neurosci Res. 2009 Sep;65(1):98-106
pubmed: 19523997
Lancet Neurol. 2009 Oct;8(10):929-37
pubmed: 19709931
Biochem Biophys Res Commun. 2009 Dec 18;390(3):947-51
pubmed: 19852934
J Mol Med (Berl). 2010 Mar;88(3):297-308
pubmed: 19921501
J Neurochem. 2010 Aug;114(3):853-63
pubmed: 20492352
Lancet Neurol. 2010 Nov;9(11):1106-17
pubmed: 20880751
Indian J Pharmacol. 2010 Oct;42(5):329
pubmed: 21206631
J Biol Chem. 2011 Sep 30;286(39):34015-22
pubmed: 21849494
Neuropsychopharmacology. 2012 Jan;37(1):213-46
pubmed: 21956442
Toxins (Basel). 2010 Nov;2(11):2622-44
pubmed: 22069568
Clin Interv Aging. 2012;7:83-8
pubmed: 22500116
Neurosci Res. 2012 Oct;74(2):156-67
pubmed: 22967672
J Neurochem. 2013 Jan;124(1):36-44
pubmed: 23106494
Methods Mol Biol. 2013;1010:177-200
pubmed: 23754226
Brain Res Bull. 2014 Feb;101:37-44
pubmed: 24365489
Neurosci Res. 2014 Jul;84:1-9
pubmed: 24815514
Mov Disord. 2014 Nov;29(13):1583-90
pubmed: 24976103
Biol Trace Elem Res. 2014 Dec;162(1-3):211-8
pubmed: 25319005
Neuroreport. 2015 Jan 21;26(2):74-80
pubmed: 25514384
Brain Struct Funct. 2015;220(3):1825-38
pubmed: 25665801
Neuropharmacology. 2016 Feb;101:576-89
pubmed: 25963416
Br Med Bull. 2015 Jun;114(1):39-52
pubmed: 25995343
Prog Neurobiol. 2017 Aug;155:96-119
pubmed: 26455458
Int J Neuropsychopharmacol. 2016 Aug 12;19(8):
pubmed: 26945022
J Neurochem. 2016 Oct;139 Suppl 1:318-324
pubmed: 27401947
CNS Neurol Disord Drug Targets. 2016;15(10):1325-1332
pubmed: 27488420
Trends Mol Med. 2016 Nov;22(11):983-993
pubmed: 27720365
Behav Brain Res. 2017 Mar 1;320:365-373
pubmed: 27825895
Immunopharmacol Immunotoxicol. 2017 Apr;39(2):80-86
pubmed: 28162057
Int J Mol Sci. 2017 Mar 04;18(3):
pubmed: 28273839
Behav Brain Res. 2017 Aug 14;332:327-336
pubmed: 28634107
Spine (Phila Pa 1976). 2018 Mar 15;43(6):E327-E333
pubmed: 28767631
J Neuroimmunol. 2017 Sep 15;310:103-106
pubmed: 28778432
Exp Neurol. 2018 Jan;299(Pt A):137-147
pubmed: 29056363
Cell Physiol Biochem. 2017;44(2):532-553
pubmed: 29145191
Mol Brain. 2017 Nov 28;10(1):53
pubmed: 29183391
Mov Disord. 2018 Jul;33(6):867-876
pubmed: 29219207
BMC Biotechnol. 2018 Jun 11;18(1):39
pubmed: 29890980
Neurotox Res. 2018 Oct;34(3):627-639
pubmed: 29934756
Brain Res. 1979 Apr 13;165(2):354-7
pubmed: 84699
Brain Res. 1996 Dec 2;742(1-2):80-8
pubmed: 9117424
Exp Neurol. 1997 Jun;145(2 Pt 1):546-54
pubmed: 9217090
J Cell Biol. 1979 Sep;82(3):798-810
pubmed: 92475
Brain Res Mol Brain Res. 1998 Jun 1;57(1):1-9
pubmed: 9630473
Exp Neurol. 1998 Aug;152(2):259-77
pubmed: 9710526